⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 20, 2024AgingOpen Access

Shexiang tongxin dropping pill alleviates myocardial injury induced by coronary microembolization by down-regulating APOC1 to inhibit STAT3 signaling pathway

Yangui Wang Tao Wang Tingting Ma Jin Zhao Weigang Qi

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study determines to validate the mechanism of Shexiang Tongxin dropping pill (STDP) in attenuating coronary microembolization (CME) induced myocardial injury.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e694aeb6db64358761af59 https://doi.org/10.18632/aging.205796

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Exploration of the effect and mechanism of Shexiang Tongxin Dropping Pill on coronary microvascular dysfunction2024
2Establishment of CME Mouse Model Based on Autologous Thrombotic Particles and the Effect of Shexiang Tongxin Dropping Pill on the Coronary Microvascular Blood Flow in This Model2024 · 2 citations
3Shexiang Tongxin Dropping Pill Protects Against Chronic Heart Failure in Mice via Inhibiting the ERK/MAPK and TGF-β Signaling Pathwayspreclinical · 2021 · 16 citations
4Shexiang Tongxin Dropping Pills Promote Macrophage Polarization-Induced Angiogenesis Against Coronary Microvascular Dysfunction via PI3K/Akt/mTORC1 Pathwaypreclinical · 2022 · 26 citations
5Shexiang Tongxin Dropping Pill Improves Peripheral Microvascular Blood Flow via Cystathionine-γ-Lyasepreclinical · 2019 · 10 citations